Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Lilly’s Trulicity reduces heart risks in clinical study

Eli Lilly.’s top-selling diabetes drug Trulicity significantly reduced the risk of heart attack, stroke and heart-related death in a broad range of people with type 2 diabetes in a large clinical trial.

Read More »

Llama Antibody Could Be The Key To Universal Flu Vaccine

New research indicates that llamas may hold the key to flu vaccines.

Read More »

AbbVie, Roche combo treatment meets main goal of leukemia trial

AbbVie and Roche’s targeted therapy delayed the progression of a type of blood and bone marrow cancer when used in combination with the Swiss drugmaker’s cancer drug in a late-stage trial.

Read More »

Long-lasting HIV injection is a step closer after second GSK study

A once-monthly injection to control HIV proved as effective as daily pills in a second study by GlaxoSmithKline, paving the way for a new regimen that could be simpler for some patients.

Read More »

Darzalex Dazzles in Multiple Myeloma Late-Stage Trial

Denmark-based Genmab released top-line data from the Phase III MAIA clinical trial of Darzalex (daratumumab), a drug licensed to Johnson & Johnson’s Janssen.

Read More »

Lundbeck Schizophrenia Drug Fails Phase III Study

Lundbeck’s shares plunged after announcing the new drug candidate Lu AF35700 for treatment-resistant schizophrenia failed to differentiate itself against conventional therapies in Phase III.

Read More »

Ultragenyx Plunges With Phase III Trial Failure

Ultragenyx shares were down after announcing the Phase III drug candidate UX007 failed to hit the mark as a treatment for patients with glucose transporter type-1 deficiency syndrome (Glut1 DS) who are experiencing disabling paroxysmal movement disorders.

Read More »

Bayer, Orion drug delays spread of prostate cancer

German’s Bayer and Finland’s Orion said a study showed the prostate cancer drug darolutamide that the companies are developing can delay the spread of the disease to other body parts.

Read More »

Pfizer and Lilly non-opioid drug helps reduce osteoarthritis pain

Tanezumab, a non-opioid drug developed by Pfizer and Eli Lilly, met the main goals of a late-stage study in which over half of patients reported a significant reduction in hip or knee osteoarthritis pain.

Read More »

AbbVie RA drug succeeds in late-stage trial

Upadacitinib, in development for rheumatoid arthritis (RA), showed significant improvement in physical function, pain and quality of life versus the commonly prescribed generic methotrexate.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2018 Focus: Top 50 Pharma, Company of the Year and more!

Subscribe

Ad Right Bottom